Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Patel v. Seattle Genetics, Inc. et al
Case Number:
2:17-cv-00041
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
January 08, 2018
Seattle Genetics Mounts 3rd Bid To Defeat Stock Fraud Suit
Cancer-drug maker Seattle Genetics Inc. on Friday asked a Washington federal court for a third time to dismiss a proposed securities fraud class action against it, saying the latest complaint still doesn't spell out how it supposedly knew it was engaged in wrongdoing.
-
October 19, 2017
Cancer Drug Maker Ends Stock Drop Action, For Now
A Washington federal judge on Wednesday tossed a shareholder suit claiming a biotechnology company misled investors about the viability of its new leukemia treatment and concealed concerns the drug causes liver damage, finding the investors hadn't sufficiently alleged the company intended to mislead them, but left the door open for them to amend their complaint.
-
January 11, 2017
Biotech Co. Hid Cancer Drug Concerns, Investors Say
A cancer therapy developer led shareholders to believe testing for its new leukemia treatment drug was going smoothly despite the U.S. Food and Drug Administration's concerns that the drug causes liver damage, leading to decreased share values, a putative class alleged in Washington federal court Tuesday.